Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Cumulus Neuroscience Presents Data at AAIC 2024 Annual Meeting and Technology…
"While clinic-based biomarkers are effective in tracking disease progression and therapeutic efficacy in clinical research, they are not scalable and lack objectivity," said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. "Our CNS-101 study was executed in collaboration with the Cumulus Pharma Advisory Group which is comprised of leading scientists from ten top pharma companies. It has validated that patients living with Alzheimer's dementia are capable and…
PR Newswire
01/08/2024
FLEXSYS TO INCREASE PRICES FOR INSOLUBLE SULFUR, 6PPD AND 4-ADPA PRODUCTS…
Furthermore, Flexsys is making significant investments in the innovation of a Next Generation Antidegradant as a replacement for 6PPD to respond to customers' requests for a more sustainable Antidegradant for tires of the future. Furthermore, Flexsys is making significant investments in the innovation of a Next Generation Antidegradant as a replacement for 6PPD to respond to customers' requests for a more sustainable Antidegradant for tires of the future. Collectively, these actions will...
PR Newswire
01/08/2024
ENGWE Launches L20 Boost ebike: Empowering Short Trips with the "BOOST" Button
With the brand slogan "Explore a new way," ENGWE aims to redefine short-distance travel, making it more accessible and enjoyable for urban commuters and recreational riders alike. so the ENGWE L20 Boost fat tire ebike is crafted to elevate every journey with seamless hill-climbing capabilities and a smooth, responsive riding experience. The upgraded "Boost" function effortlessly tackles inclines up to 17.8% with the touch of a button, meeting all your daily commuting and…
PR Newswire
01/08/2024
Leqembi revenue more than doubled - totaled JPY 6.3 billion in the second…
BioArctic's report for the second quarter 2024 will be published on August 29 at 08.00 a.m. CET. BioArctic's report for the second quarter 2024 will be published onAugust 29at08.00 a.m. CET. This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons below, onAugust 1, 2024, at12.45 p.m. CET. For further...
PR Newswire
01/08/2024
uniQure Announces Second Quarter 2024 Financial Results and Provides Company…
~ Announced RMAT designation for AMT-130 in Huntington's disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of neurodegeneration; Meeting with FDA expected in the second half of 2024 to discuss potential for expedited clinical development ~ ~ Initiated patient screening for three additional Phase I/II studies in mesial temporal lobe epilepsy, SOD1 ALS, and Fabry disease ~~ Today, announced an organizational...
Nasdaq GlobeNewswire
01/08/2024
Aurora Cannabis and Vectura Fertin Pharma, Inc. announce commercial…
Aurora Cannabis and Vectura Fertin Pharma, Inc. announce commercial collaborationCollaboration will initially see launch of a new CBD lozenge from Cogent International, a Vectura Fertin Pharma subsidiary, on Aurora's Canadian medical cannabis patient platformFollowing successful launch of CBD lozenge, the collaboration will explore the potential to launch Vectura Fertin Pharma's future medical cannabis portfolio in CanadaEdmonton, AB, and Stamford, CT – August 1, 2024- Aurora...
Nasdaq GlobeNewswire
01/08/2024
Compass Pathways announces second quarter 2024 financial results and business…
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024Gino Santini to join Board of Directors as ChairmanLori Englebert named new Chief Commercial OfficerCash position of $228.6 millionConference call August 1 at 8:00 am ET (1:00 pm UK) LONDON and NEW YORK, Aug.01, 2024(GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access...
Nasdaq GlobeNewswire
01/08/2024
UV-Absorbing Chemicals for Cosmetics Market to Reach US$ 1.1 Billion by 2034…
UV-absorbing substances shield the skin from UV rays by reflecting or absorbing them. They are used in a variety of cosmetic goods, including over-the-counter sunscreens and other items for personal hygiene. UV-absorbing substances shield the skin from UV rays by reflecting or absorbing them. They are used in a variety of cosmetic goods, including over-the-counter sunscreens and other items for personal hygiene. Sunscreen products are mainly utilized in situations where complete protection...
PR Newswire
01/08/2024
Nucleic Acid Therapeutics Market to Reach USD 22.1 Billion by 2034, Advances in…
Advances in genetic research and biotechnology are propelling the nucleic acid therapeutics market value. These medicines, which include antisense oligonucleotides (ASOs), RNA interference (RNAi), and RNA aptamers, provide targeted treatments for a range of genetic abnormalities, infectious diseases, and malignancies. Advances in genetic research and biotechnology are propelling the nucleic acid therapeutics market value. These medicines, which include antisense oligonucleotides (ASOs), RNA...
PR Newswire
01/08/2024
Infusion Pump Market is expected to reach USD 209.8 Million by 2034, growing at…
The aging population is expected to drive the demand for infusion pumps over the forecast period. As people age, they are more likely to require medical treatment, which can include the use of infusion pumps. In addition, the elderly population is more likely to suffer from chronic diseases, further driving the demand for these devices. The aging population is expected to drive the demand for infusion pumps over the forecast period. As people age, they are more likely to require medical...
PR Newswire
01/08/2024
President of Ghana Marks Successful LiuGong Equipment Delivery
"Ghana is at a critical stage of rapid development. To achieve economic takeoff, it is essential to first address the key issue of infrastructure construction. The government's procurement of a thousand units of LiuGong equipment has profound significance for improving transportation conditions in our rural areas and enhancing local livelihoods." " Ghanais at a critical stage of rapid development. To achieve economic takeoff, it is essential to first address the key issue of…
PR Newswire
01/08/2024
VERSACE HOME DRESSES RGZ DEVELOPERS LUXULY VILLAS WITH HAUTE COUTURE
About Versace Home About Versace Home Versace Home extends Versace's fashion design vision to a way of living. The same energy, refinement, and signature modernity of Versace fashion collections are reflected through a complete home and lifestyle design collection that includes furniture, textiles, porcelain, glassware, interior décor, and more. True icons of Versace such as the Medusa, Greca, and Barocco, are as immediately recognizable and powerful across the back of an armchair,...
PR Newswire
01/08/2024
Immunovia completes development of its pancreatic cancer detection test after…
A sensitivity of 85% means the new test is capable of detecting pancreatic cancer in approximately 6 out of every 7 people with early-stage disease. Specificity of 98% means this new test should return a false positive result just once for every 50 people tested who do not have pancreatic cancer. Test performance was refined by leveraging additional samples with more complete and detailed clinical information and through more sophisticated statistical modeling. Test performance was independently…
PR Newswire
01/08/2024
Premium Trendy Products, Direct Sourcing, Efficient Matchmaking - Don't Miss the…
The fair will highlight the latest trends and high-quality products in the kids industry across eight major categories, including prams & accessories, children's car seats, ride-on products, baby furniture & home items, baby feeding & nursery products, health care and bathing products, home safety products, and infant toys. 8,000+ international buyers from 130+ countries and regions are expected to attend. The fair will highlight the latest trends and high-quality products in…
PR Newswire
01/08/2024
WuXi Biologics' Four Manufacturing Facilities and Biosafety Testing Center…
WuXi Biologics has a proven track record of strict quality compliance. Since 2017, the company has completed and passed 35 global regulatory agency inspections, more than 1,250 GMP quality audits by global clients, and more than 145 audits by EU Qualified Persons. Currently, WuXi Biologics has 15 GMP-certified drug substance and drug product facilities in its global network. WuXi Biologics has a proven track record of strict quality compliance. Since 2017, the company has completed and passed...
PR Newswire
01/08/2024
Novo Holdings Invests in UK-Listed Oxford Nanopore Technologies
Dr Daniel Mahony, Senior Partner, Growth Investments, Novo Holdings, said: "Oxford Nanopore has made impressive ongoing progress to advance its technology platform and gain commercial traction. This investment underscores our belief in Oxford Nanopore's platform and its expanding opportunity in biopharmaceuticals, where rapid sequencing, richer data and a streamlined platform can support discovery and delivery of new drug therapies. We are confident in Oxford Nanopore's long-term value…
PR Newswire
01/08/2024
CMR Surgical embarks on world-first paediatric clinical trial using Versius
CMR Surgical embarks on world-first paediatric clinical trial using VersiusCMR Surgical has commenced the world's first multicentre prospective clinical trial on the use of Versius in paediatric surgery Led by Mr Ewan Brownlee, Consultant Paediatric Urologist at the Southampton Children's Hospital, part of the University Hospital Southampton NHS Foundation Trust, the prospective clinical study will assess the safety and efficacy of Versius, for use in urological procedures in...
Nasdaq GlobeNewswire
01/08/2024
IBA Notice of Half Year 2024 Results and Conference Call
HY24 results webcast to take place onThursday, 29 August 2024 at 3pm CEST Louvain-la-Neuve, Belgium, 1 August 2024- IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the half year 2024 onThursday, 29 August 2024 at 7am CEST.Conference Call Information IBA's management team will host a conference call and webcast conducted in English to present the half year...
Nasdaq GlobeNewswire
01/08/2024
Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the…
Valneva obtains exclusive worldwide license for LimmaTech's S4VShigellavaccine candidate and adds an attractive Phase 2 clinical asset to Valneva's R&D pipelineLimmaTech to receive upfront payment, is eligible for future milestone and royalty payments, and will collaborate on S4V clinical development through Phase 2Valneva will host a live webcast on this announcement at 3 p.m. CEST/9 a.m. EDT today. Please refer to this link: ...
Nasdaq GlobeNewswire
01/08/2024
Pharming Group reports second quarter and first half 2024 financial results and…
Second quarter 2024 total revenues increased by 35% to US$74.1 million, compared to the second quarter 2023, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue increased by 23% to US$63.0 million, compared to the second quarter 2023Joenja® (leniolisib) second quarter revenue increased by 16% to US$11.1 million, compared to the first quarter 2024 First half total revenues increased by 33% to US$129.7 million, compared to the first half 2023On...
Nasdaq GlobeNewswire
01/08/2024
Fagron delivers strong performance with 16% topline growth and 17% increase in…
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 1 August 2024 – 7:00 AM CET Fagron delivers strong performance with 16% topline growth and 17% increase in REBITDA for the first half of 2024 Fagron, the leading global player in pharmaceutical compounding today publishes its first half results for the period ending 30 June 2024. Key Highlights Strong topline performance with 15.5% reported revenue growth (15.3% at Constant Exchange Rates...
Nasdaq GlobeNewswire
01/08/2024
Sirnaomics Announces a Partnership with Gore Range Capital for Establishment of…
Frederick Beddingfield, MD, PhD, serving as Chairperson of the board of directors of Sagesse Bio, is an internationally renowned dermatologist and expert in biopharma and the aesthetics industry, who has led the development of global leading brands such as BOTOX®, JUVEDERM®, LATISSE® and KYBELLA®. He served as Chief Medical Officer of Allergan Medical and Kythera, and as CEO of Sienna Bio and Kira Pharmaceuticals, and currently serves on the board of directors of Cytrellis Biosystems. Dr…
PR Newswire
01/08/2024
Prestige Biopharma's Herceptin Biosimilar Tuznue® Receives Positive CHMP Opinion…
Prestige Biopharma has already established licensing agreements with major pharmaceutical partners for global marketing and sales. These agreements are set to generate immediate milestone payments and provide early revenue for the company. Negotiations are also underway to ensure a strong market entry for Tuznue® in Europe. Prestige Biopharma has already established licensing agreements with major pharmaceutical partners for global marketing and sales. These agreements are set to generate...
PR Newswire
01/08/2024
Endo Announces Effectiveness of Form S-1 Registration Statement for Existing…
Endo, which is focused on creating long-term value for stakeholders through a diversified portfolio of on-market medicines and a pipeline of innovative and differentiated product candidates, is targeting to have the Company's shares of common stock begin trading on the New York Stock Exchange (NYSE) later in 2024, subject to required approvals and other customary conditions. Endo, which is focused on creating long-term value for stakeholders through a diversified portfolio of on-market...
PR Newswire
31/07/2024
Altri Comunicati
